{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:38:30Z","timestamp":1793313510684,"version":"4.5.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Population Health Management"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>\n                    More than 16 million Americans living with cognitive impairment warrant a diagnostic evaluation to determine the cause of this disorder. The recent availability of disease-modifying therapies for Alzheimer's disease (AD) is expected to significantly drive demand for such diagnostic testing. Accurate, accessible, and affordable methods are needed. Blood biomarkers (BBMs) offer advantages over usual care amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers in these regards. This study used a budget impact model to assess the economic utility of the PrecivityAD\n                    <jats:sup>\u00ae<\/jats:sup>\n                    blood test, a clinically validated BBM test for the evaluation of brain amyloid, a pathological hallmark of AD. The model compared 2 scenarios: (1) baseline testing involving usual care practice, and (2) early use of a BBM test before usual care CSF and PET biomarker use. At a modest 40% adoption rate, the BBM test scenario had comparable sensitivity and specificity to the usual care scenario and showed net savings in the diagnostic work-up of $3.57 million or $0.30 per member per month in a 1 million member population, translating to over $1B when extrapolated to the US population as a whole and representing a 11.4% cost reduction. Savings were driven by reductions in the frequency and need for CSF and PET testing. Additionally, BBM testing was associated with a cost savings of $643 per AD case identified. Use of the PrecivityAD blood test in the clinical care pathway may prevent unnecessary testing, provide cost savings, and reduce the burden on both patients and health plans.\n                  <\/jats:p>","DOI":"10.1089\/pop.2023.0309","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T10:31:17Z","timestamp":1711621877000},"page":"174-184","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment"],"prefix":"10.1177","volume":"27","author":[{"given":"William J.","family":"Canestaro","sequence":"first","affiliation":[{"name":"Department of Management and Organization, Foster School of Business, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-4415","authenticated-orcid":false,"given":"Mark","family":"Monane","sequence":"additional","affiliation":[{"name":"C, 2N Diagnostics, LLC, St. Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"C, 2N Diagnostics, LLC, St. Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.06.019"},{"key":"e_1_3_5_4_2","unstructured":"Alzheimer's Association. What is Alzheimer's Disease?. 2023. Available from: https:\/\/www.alz.org\/alzheimers-dementia\/what-is-alzheimers [Last accessed: November4 2023]."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1428\/3\/jpad.2021.23"},{"key":"e_1_3_5_6_2","unstructured":"The Use of MRI and PET for Clinical Diagnosis of Dementia and Investigation of Cognitive Impairment: A Consensus Report. 2021. Available from: https:\/\/www.alz.org\/national\/documents\/imaging_consensus_report.pdf [Last accessed: October1 2023]."},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.18.2219"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00008"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01272-z"},{"issue":"3","key":"e_1_3_5_12_2","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's Treatment","volume":"8","author":"Hlavka JP","year":"2019","unstructured":"Hlavka JP, , Mattke S, , Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's Treatment. Rand Health Q, 2019; 8(3):2.","journal-title":"Rand Health Q"},{"issue":"1","key":"e_1_3_5_13_2","article-title":"Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times","volume":"12","author":"Mattke S","year":"2020","unstructured":"Mattke S, , Cho SK, , Bittner T, et al. Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times. Alzheimers Dement Diagn Assessment Dis Monit, 2020; 12(1):e12081.","journal-title":"Alzheimers Dement Diagn Assessment Dis Monit"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.017"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.05.011"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8392"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51863"},{"key":"e_1_3_5_18_2","unstructured":"Petersen RC. Mild cognitive impairment: Epidemiology pathology and clinical assessment. Available from: https:\/\/www.uptodate.com\/contents\/mild-cognitive-impairment-epidemiology-pathology-and-clinical-assessment [Last accessed: February2 2024]."},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0243-0"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12846"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.001"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-1-201301010-00006"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004826"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S228939"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36030"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2023.0039"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2013.0096"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2021.0185"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_5_31_2","unstructured":"2019 U.S. Population Estimates Continue to Show the Nation's Growth Is Slowing. Available from: https:\/\/www.census.gov\/newsroom\/press-releases\/2019\/popest-nation.html [Last accessed: October11 2023]."},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12470"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.10.001"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acn.2004.11.004"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828726f5"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00530-1"},{"key":"e_1_3_5_37_2","unstructured":"Evaluation of Automatic Class Ill Designation for Lumipulse G 13-Amyloid Ratio (1\u201342\/1\u201340) Decision Summary. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN200072.pdf [Last accessed: December 11 2023]."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2000"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4669"},{"key":"e_1_3_5_41_2","unstructured":"Physician Fee Schedule Guide. Centers for Medicare & Medicaid Services. 2023. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search [Last accessed: December11 2023]."},{"key":"e_1_3_5_42_2","unstructured":"Congressional Budget Office. The Prices That Commercial Health Insurers and Medicare Pay for Hospitals' and Physicians' Services. Available from: https:\/\/www.cbo.gov\/system\/files\/2022-01\/57422-medical-prices.pdf [Last accessed: January23 2024]."},{"key":"e_1_3_5_43_2","unstructured":"Pe\u00f1a MT Mohamed M Burns A et al. A Profile of Medicare-Medicaid Enrollees (Dual Eligibles). Available from: https:\/\/www.kff.org\/medicare\/issue-brief\/a-profile-of-medicare-medicaid-enrollees-dual-eligibles [Last accessed: January23 2024]."},{"key":"e_1_3_5_44_2","unstructured":"Medicaid Reimbursement Is Not Keeping Pace With Medicare. American College of Radiology. 2023. Available from: https:\/\/www.acr.org\/Practice-Management-Quality-Informatics\/ACR-Bulletin\/Articles\/June-2023\/Medicaid-Reimbursement-Is-Not-Keeping-Pace-With-Medicare [Last accessed: January24 2024]."}],"container-title":["Population Health Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pop.2023.0309","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pop.2023.0309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pop.2023.0309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:26:49Z","timestamp":1777685209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/pop.2023.0309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1089\/pop.2023.0309"],"URL":"https:\/\/doi.org\/10.1089\/pop.2023.0309","relation":{},"ISSN":["1942-7891","1942-7905"],"issn-type":[{"value":"1942-7891","type":"print"},{"value":"1942-7905","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}